Pfizer's COVID-19 vaccine generated $3.5 billion in revenue in the first quarter of 2021, which was nearly a fourth of the company's $14.6 billion income during the period, the pharmaceutical giant reported in an earnings call Tuesday.
Why it matters: The vaccine was the biggest source of revenue for Pfizer — which, unlike some of its competitors — elected to collect the profit from sales of its vaccine, the New York Times notes.
Get market news worthy of your time with Axios Markets. Subscribe for free.
Pfizer's operational revenues grew by 8% in the first few months of the year.
Also unlike some of its competitors, the company did not to take federal funds from the Trump administration's Operation Warp Speed.
Vaccines produced by China, India and Russia have become the primary source of doses delivered to poorer nations.
Pfizer announced Tuesday it has shipped 430 million doses of the vaccine to 91 countries and territories around the world, though it did not specify how much have gone to developing nations.
Like this article? Get more from Axios and subscribe to Axios Markets for free.